Last: | |||
Change: | Change(%): | ||
Volume: | Open: | ||
High: | Low: | ||
52Wk High: | 52Wk Low: |
GW is the global leader in developing cannabinoid-based medicines. Its lead product candidate, Epidiolex® (cannabidiol), is in development to treat rare and catastrophic forms of childhood-onset epilepsy, potentially offering relief to patients for conditions that previously had few treatment options.